Home > Resources > Whitepapers > CARING FOR QUALITY IN HEALTH

CARING FOR QUALITY IN HEALTH

November 14, 2018

This synthesis report draws on key lessons from the OECD Health Care Quality Review series. As health costs continue to climb, policymakers increasingly face the challenge of ensuring that substantial spending on health is delivering value for money. At the same time, concerns about patients occasionally receiving poor‑quality health care have led to demands for greater transparency and accountability.

Spotlight

Symphogen

Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use. The European-based company is developing next-generation antibody therapeutics for the treatment of cancer. Symphogen is dedicated to bringing truly innovative oncology products to the market, creating optimally selected antibody mixtures that address multiple oncology targets in a single drug product.

OTHER WHITEPAPERS

How Can Biotechnology and Pharmaceutical Industries Better Weather This New Economy?

whitePaper | October 10, 2022

Biotechnology and pharmaceutical industries continue to experience increased pressure on financial performance due to several factors.

Challenges and Solutions for Gene Therapy manufacturing

whitePaper | November 17, 2022

Gene therapy is the modification of specific genes in targeted cells in order to address genetic mutations that cause some of the most debilitating human conditions.

Scalable Rubella production in scale-X™ bioreactor with MRC-5 cells

whitePaper | November 18, 2022

Due to vaccine delivery gap for Rubella disease, global immunization is still limited in some parts of the world. In this paper we will demonstrate how one scale-X™ carbo fixed-bed bioreactor system.

DIGITAL BIOTECH IS MISSION-CRITICAL TO MODERNA

whitePaper | May 20, 2022

We are living in a unique time in which the world is changing faster than ever. This largely is due to an influx and infusion of digital technologies that are reinventing and reimagining businesses across nearly every sector, and dramatically shifting societal and economic interactions. While the life science industry has, to some extent, adopted various digital technologies, it has not had a significant digital transformation in how it does business.

Advanced Treatments Gene and Cell Therapy

whitePaper | April 26, 2022

Public Policy Projects (PPP) is a global policy institute offering practical analysis and development across a range of sectors, including health and social care.

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans